News and Events - Page 7 of 11 - Precision Biologics

15JulJuly 15, 2020

Evaluation of the Anti-Tumor Activity of the Humanized Monoclonal Antibody NEO-201 in Preclinical Models of Ovarian Cancer

Precision Biologics in conjunction with our research collaborators at the National Cancer Institute (NCI) have...

22JunJune 22, 2020

Precision Biologics along with our collaborators at the National Cancer Institute present research data using...

30AprApril 30, 2020

Precision Biologics announces that the results of the Phase II Clinical Trial using its lead...

01MarMarch 1, 2020

Dr Massimo Fantini, Senior Scientist is Presenting the following Talk entitled: "Mechanisms of action of...

25FebFebruary 25, 2020

Ariel Cahill Hollinshead Hyun, PhD, a pioneering cancer researcher whose work contributed to the foundation...

07FebFebruary 7, 2020

NEO-201 is an IgG1 mAb targeting variants of CEACAM5/6 that demonstrates tumor sensitivity and specificity....

23JanJanuary 23, 2020

This is a first-in-human phase 1 study to determine the maximum tolerated dose (MTD) and...

16JanJanuary 16, 2020

The Monoclonal Antibody NEO-201 Enhances Natural Killer Cell Cytotoxicity Against Tumor Cells Through Blockade of...

17DecDecember 17, 2019

Most monoclonal antibody cancer therapies are developed for known targets and are commercially approved for...

06NovNovember 6, 2019

An anti-carcinoma monoclonal antibody (mAb) NEO-201 can also target and eliminate human immunosuppressive regulatory T...